VF
NBIX icon

Virtu Financial’s Neurocrine Biosciences NBIX Stock Holding History

Virtu Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Sell
9,570
-5,819
-38% -$772K 0.05% 249
2025
Q4 		$2.18M Buy
15,389
+13,632
+776% +$1.97M 0.08% 146
2025
Q3 		$247K Buy
+1,757
New +$238K 0.01% 830
2024
Q4 		– Sell
-17,230
Closed -$1.99M – 1870
2024
Q3 		$1.99M Buy
+17,230
New +$2.36M 0.11% 143
2024
Q2 		– Sell
-4,212
Closed -$581K – 1689
2024
Q1 		$581K Buy
+4,212
New +$575K 0.04% 380
2023
Q3 		– Sell
-5,353
Closed -$505K – 1671
2023
Q2 		$505K Buy
+5,353
New +$523K 0.04% 397
2021
Q3 		– Sell
-6,410
Closed -$624K – 1799
2021
Q2 		$624K Buy
6,410
+1,895
+42% +$182K 0.06% 379
2021
Q1 		$439K Sell
4,515
-1,527
-25% -$160K 0.03% 586
2020
Q4 		$579K Sell
6,042
-13,877
-70% -$1.34M 0.06% 395
2020
Q3 		$1.92M Buy
19,919
+13,655
+218% +$1.58M 0.33% 48
2020
Q2 		$764K Buy
+6,264
New +$692K 0.09% 252
2019
Q4 		– Sell
-4,695
Closed -$423K – 1703
2019
Q3 		$423K Buy
+4,695
New +$439K 0.03% 581
2019
Q2 		– Sell
-9,211
Closed -$812K – 1712
2019
Q1 		$812K Buy
+9,211
New +$770K 0.05% 375
2018
Q4 		– Sell
-4,114
Closed -$506K – 1840
2018
Q3 		$506K Sell
4,114
-3,177
-44% -$360K 0.03% 599
2018
Q2 		$716K Sell
7,291
-8,450
-54% -$756K 0.04% 591
2018
Q1 		$1.3M Buy
+15,741
New +$1.33M 0.07% 275

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's NBIX Position: Q1 2026 in Review

Virtu Financial reduced its Neurocrine Biosciences (NBIX) stake by 38% in Q1 2026, selling an estimated $772K and leaving 9,570 shares worth $1.26M. The position accounts for 0.05% of the portfolio, ranked #249.

Virtu Financial first reported a position in NBIX in Q1 2018 and has held it in 16 quarters since. The position peaked at $2.18M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Virtu Financial held 9,570 shares of Neurocrine Biosciences worth $1.26M as of Q1 2026.
  • Virtu Financial sold 5,819 Neurocrine Biosciences shares in Q1 2026, an estimated $772K.
  • Neurocrine Biosciences made up 0.05% of Virtu Financial's portfolio in Q1 2026, its #249 holding.
  • Virtu Financial first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 16 quarters since.
  • Virtu Financial's Neurocrine Biosciences position peaked at $2.18M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.